Delving into the Latest Updates on Velmupressin with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

velmupressin

+ [1]

Target

AVPR2

Mechanism

AVPR2 agonists(Vasopressin V2 receptor agonists)

Therapeutic Areas

Urogenital DiseasesOther Diseases

Active Indication-

Inactive Indication

NocturiaPolyuria

Originator Organization

Ferring BV

Active Organization-

Inactive Organization

Ferring Pharmaceuticals A/S

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC42H60ClN11O8S2

InChIKeyVXHQBKSIDHVNIG-ZABOXFJKSA-N

CAS Registry1647119-61-6

Gene Sequence

Sequence Code 526207387

Source: *****

A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults

The purpose of this trial was to investigate the efficacy, safety and tolerability of different oral doses of FE 201836, with desmopressin as a benchmark, during 12 weeks of treatment for nocturia due to nocturnal polyuria in adults

Start Date27 Jul 2017

Sponsor / Collaborator

Ferring Pharmaceuticals A/S

NL-OMON43334 / CompletedNot Applicable

An open-label, 3 doses fixed sequence trial investigating safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral and intravenous administrations of FE 201836 in elderly subjects - FE 201836 Safety, PK, PD Study

Start Date09 Nov 2016

Sponsor / Collaborator

Ferring Pharmaceuticals A/S

NL-OMON43629 / CompletedNot Applicable

A double-blind, placebo controlled, randomised, parallel group study with an open-label cross-over part, investigating safety, tolerability, pharmacokinetics, and pharmacodynamics after single ascending oral doses and a single intravenous dose of the vasopressin V2-receptor agonist FE 201836 - FE 201836 SAD and cross-over study

Start Date14 Jul 2015

Sponsor / Collaborator

Ferring Pharmaceuticals SA

100 Clinical Results associated with Velmupressin

Login to view more data

100 Translational Medicine associated with Velmupressin

Login to view more data

100 Patents (Medical) associated with Velmupressin

Login to view more data

100 Deals associated with Velmupressin

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nocturia	Phase 2	CZ	Ferring Pharmaceuticals A/S	27 Jul 2017
Nocturia	Phase 2	PL	Ferring Pharmaceuticals A/S	27 Jul 2017
Nocturia	Phase 2	DE	Ferring Pharmaceuticals A/S	27 Jul 2017
Nocturia	Phase 2	CA	Ferring Pharmaceuticals A/S	27 Jul 2017
Nocturia	Phase 2	HU	Ferring Pharmaceuticals A/S	27 Jul 2017
Nocturia	Phase 2	BE	Ferring Pharmaceuticals A/S	27 Jul 2017
Nocturia	Phase 2	US	Ferring Pharmaceuticals A/S	27 Jul 2017
Polyuria	Phase 2	HU	Ferring Pharmaceuticals A/S	27 Jul 2017
Polyuria	Phase 2	CZ	Ferring Pharmaceuticals A/S	27 Jul 2017
Polyuria	Phase 2	CA	Ferring Pharmaceuticals A/S	27 Jul 2017